Hugo L Paz Y Mar1, Stanley L Hazen2, Russell P Tracy3, Kingman P Strohl4, Dennis Auckley5, James Bena6, Lu Wang6, Harneet K Walia1, Sanjay R Patel7, Reena Mehra8. 1. Sleep Disorders Center, Neurological Institute, Cleveland Clinic, Cleveland, OH. 2. Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. 3. Departments of Biochemistry and Pathology, University of Vermont, Burlington, VT. 4. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH. 5. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, MetroHealth Medical Center, Cleveland, OH. 6. Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. 7. Division of Sleep and Circadian Disorders, Brigham and Women's Hospital and Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. 8. Sleep Disorders Center, Neurological Institute, Cleveland Clinic, Cleveland, OH; Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH. Electronic address: mehrar@ccf.org.
Abstract
BACKGROUND: Although existing research highlights the relationship of OSA and cardiovascular disease, the effect of OSA treatment on cardiovascular biomarkers remains unclear. We evaluated the effect of OSA treatment on oxidative stress/inflammation measures. METHODS: We conducted a parallel, randomized controlled trial in moderate to severe OSA (apnea-hypopnea index ≥ 15) patients to examine effects of 2-month CPAP vs sham-CPAP on the primary outcome of oxidative stress/inflammation (F2-isoprostanes: ng/mg) and myeloperoxidase: pmol/L) and secondary oxidative stress measures. Exploratory secondary analyses included vascular and systemic inflammation markers. Linear models adjusted for baseline values examined effect of CPAP on biomarker change (least squares means, 95% CI) including secondary stratified analyses examining CPAP adherence and degree of hypoxia. RESULTS: Of 153 participants, 76 were randomized toCPAP and 77 to sham-CPAP. In an intent-to-treat analyses, no significant change was observed in the sham and CPAP groups respectively: F2-isoprostanes (-0.02 [-0.12 to 0.10] vs -0.08 [-0.18 to 0.03]) or myeloperoxidase (-3.33 [-17.02 to 10.37] vs -5.15 [-18.65 to 8.35]), nor other oxidative markers; findings that persisted in analyses stratified by adherence and hypoxia. Exploratory analyses revealed percentage reduction of soluble IL-6 receptor (ng/mL) levels (-0.04 [-0.08 to -0.01] vs 0.02 [-0.02 to 0.06], P = .019) and augmentation index (%) (-6.49 [-9.32 to -3.65] vs 0.44 [-2.22 to 3.10], P < .001) with CPAP compared with sham, respectively. CONCLUSIONS: In moderate to severe OSA, 2-month CPAP vs sham did not reduce oxidative stress despite consideration of a broad range of measures, positive airway pressure adherence, and hypoxia burden. These findings suggest that nonoxidative stress pathways primarily modulate OSA-related cardiovascular consequences. TRIAL REGISTRATION: ClinicalTrials.govNCT00607893.
RCT Entities:
BACKGROUND: Although existing research highlights the relationship of OSA and cardiovascular disease, the effect of OSA treatment on cardiovascular biomarkers remains unclear. We evaluated the effect of OSA treatment on oxidative stress/inflammation measures. METHODS: We conducted a parallel, randomized controlled trial in moderate to severe OSA (apnea-hypopnea index ≥ 15) patients to examine effects of 2-month CPAP vs sham-CPAP on the primary outcome of oxidative stress/inflammation (F2-isoprostanes: ng/mg) and myeloperoxidase: pmol/L) and secondary oxidative stress measures. Exploratory secondary analyses included vascular and systemic inflammation markers. Linear models adjusted for baseline values examined effect of CPAP on biomarker change (least squares means, 95% CI) including secondary stratified analyses examining CPAP adherence and degree of hypoxia. RESULTS: Of 153 participants, 76 were randomized to CPAP and 77 to sham-CPAP. In an intent-to-treat analyses, no significant change was observed in the sham and CPAP groups respectively: F2-isoprostanes (-0.02 [-0.12 to 0.10] vs -0.08 [-0.18 to 0.03]) or myeloperoxidase (-3.33 [-17.02 to 10.37] vs -5.15 [-18.65 to 8.35]), nor other oxidative markers; findings that persisted in analyses stratified by adherence and hypoxia. Exploratory analyses revealed percentage reduction of soluble IL-6 receptor (ng/mL) levels (-0.04 [-0.08 to -0.01] vs 0.02 [-0.02 to 0.06], P = .019) and augmentation index (%) (-6.49 [-9.32 to -3.65] vs 0.44 [-2.22 to 3.10], P < .001) with CPAP compared with sham, respectively. CONCLUSIONS: In moderate to severe OSA, 2-month CPAP vs sham did not reduce oxidative stress despite consideration of a broad range of measures, positive airway pressure adherence, and hypoxia burden. These findings suggest that nonoxidative stress pathways primarily modulate OSA-related cardiovascular consequences. TRIAL REGISTRATION: ClinicalTrials.govNCT00607893.
Authors: Camilla M Hoyos; Brendon J Yee; Keith K Wong; Ronald R Grunstein; Craig L Phillips Journal: Am J Hypertens Date: 2015-03-28 Impact factor: 2.689
Authors: Erna S Arnardottir; Diane C Lim; Brendan T Keenan; Greg Maislin; Bryndis Benediktsdottir; Sigurdur Juliusson; Allan I Pack; Thorarinn Gislason Journal: J Sleep Res Date: 2014-10-31 Impact factor: 3.981
Authors: Carmen M Troncoso Brindeiro; Ana Q da Silva; Kyan J Allahdadi; Victoria Youngblood; Nancy L Kanagy Journal: Am J Physiol Heart Circ Physiol Date: 2007-08-31 Impact factor: 4.733
Authors: Malcolm Kohler; Sonya Craig; Justin C T Pepperell; Debby Nicoll; Daniel J Bratton; Andrew J Nunn; Paul Leeson; John R Stradling Journal: Chest Date: 2013-09 Impact factor: 9.410
Authors: Michelle L Reid; Kevin J Gleason; Jessie P Bakker; Rui Wang; Murray A Mittleman; Susan Redline Journal: Sleep Date: 2019-08-01 Impact factor: 5.849
Authors: Bharati Prasad; Alana D Steffen; Hans P A Van Dongen; Francis M Pack; Inna Strakovsky; Bethany Staley; David F Dinges; Greg Maislin; Allan I Pack; Terri E Weaver Journal: Sleep Date: 2018-02-01 Impact factor: 5.849